Studies from I.K. Wium-Andersen et al Have Provided New Data on Type 2 Diabetes (Antidiabetic medication and risk of dementia in patients with type 2 diabetes. A nested case-control study)
Mental Health News Daily
2019 SEP 11 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health News Daily -- Research findings on Nutritional and Metabolic Diseases and Conditions - Type 2 Diabetes are discussed in a new report. According to news reporting originating from Copenhagen, Denmark, by NewsRx correspondents, research stated, “Diabetes is a risk factor for dementia, but whether antidiabetic medication decreases the risk is unclear. We examined the association between antidiabetic medication and dementia.”
Our news editors obtained a quote from the research, “We performed a nested case-control study within a cohort of all 176,250 patients registered with type 2 diabetes in the Danish National Diabetes Register between 1995-2012. This population was followed for dementia diagnosis or anti-dementia medication use until May 2018. Using risk-set sampling, each dementia case (n=11,619) was matched on followup time and calender year of dementia with four controls randomly selected among cohort members without dementia (n=46,476). Ever use and mean daily defined dose of antidiabetic medication was categorized in types (insulin, metformin, sulfonylurea and glinides combined, glitazone, dipeptidyl peptidase 4 (DPP4) inhibitors, glucagon-like peptide 1 (GLP1) analogs, sodium-glucose transport protein 2 (SGLT2) inhibitors and acarbose). Conditional logistic regression models were fitted to calculate odds ratios (ORs) for dementia associated with antidiabetic medication use, adjusting for potential confounders. Use of metformin, DPP4 inhibitors, GLP1 analogs, and SGLT2 inhibitors were associated with lower odds of dementia after multible adjustments (ORs of 0.94 (95% confidence interval (CI) 0.89-0.99), 0.80 (95%CI 0.74-0.88), 0.58 (95%CI 0.50-0.67), and 0.58 (95%CI 0.42-0.81), respectively), with a gradual decrease in odds of dementia for each increase in daily defined dose. Analyses of the most frequent treatment regimes did not show any synergistic effects of combined treatment.”
According to the news editors, the research concluded: “Use of metformin, DPP4 inhibitors, GLP1 analogs and SGLT2 inhibitors was associated with lower risk of dementia in patients with diabetes.”
For more information on this research see: Antidiabetic medication and risk of dementia in patients with type 2 diabetes. A nested case-control study. European Journal of Endocrinology, 2019;():. European Journal of Endocrinology can be contacted at: Bio Scientifica LTD, Euro House, 22 Apex Court Woodlands, Bradley Stoke, Bristol BS32 4JT, England.
The news editors report that additional information may be obtained by contacting I.K. Wium-Andersen, I Wium-Andersen, O, Psychiatric Center Copenhagen - department o, Copenhagen 0, Denmark. Additional authors for this research include M. Osler, M.B. Jorgensen, J. Rungby and M.KK Wium-Andersen.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1530/eje-19-0259. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
Publisher contact information for the European Journal of Endocrinology is: Bio Scientifica LTD, Euro House, 22 Apex Court Woodlands, Bradley Stoke, Bristol BS32 4JT, England.
(Our reports deliver fact-based news of research and discoveries from around the world.)